InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global ATMP Service Providers Market by Type of Services (Analytics/CRO (Microbiology, Endotoxin, PCR, Flow Cytometry, ELISA, Container Closure, Sterilty, and Pre-clinical), Quality (Documentation, QMS And Regulations), CMO (HQ/GMP plasmid DNA, MSC Manufacture, Pluripotent Stem Cells), Logistics (Storage, Stability And Transport)), Application (GTMP(Gene Therapy Medicinal Products), sCTMP(somatic Cells Therapy Medicinal Products) and TEP(Tissue Engineered Products))-Trends, Industry Competition Analysis, Revenue and Forecast To 2030.”
According to the latest research by InsightAce Analytic, the Global ATMP Service Providers Market is valued at US$ 13.85 Billion in 2021, and it is expected to reach US$ 34.59 Billion by 2030, with a CAGR of 10.9% during the forecast period of 2022-2030. By region, North America dominated the market with major market share in 2021.
Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1228
ATMPs, or Advanced Therapy Medicinal Products, are cutting-edge treatments created with specifically modified cells, genes, and tissues. ATMPs open the way to personalized and precise medicines that can prevent, diagnose, treat, or cure diseases at their source instead of more typical, one-size-fits-all drugs. They offer groundbreaking new opportunities to treat life-threatening diseases where one or limited doses have a curative effect. Characterization and analysis are essential in providing critical chemistry, manufacturing, and control (CMC) information for Investigational New Drug Applications in the case of ATMP services (INDs). Testing is also required as part of stability studies and to support release. Service providers support product development from early-stage to in-process control and product release assays.
The global prevalence is increasing regarding chronic diseases like diabetes, cancer, cardiovascular disease, and hereditary diseases like cystic fibrosis and others. As the demand for individualized medicine grows, technology advances in biological treatments, resulting in breakthrough Advanced Therapy Medicinal Products. This is a critical aspect of ATMP service providers’ market expansion. Most new advanced therapy products are being developed in the US and EU. Companies will look for low-cost clinical trials in emerging markets that offer innovative opportunities to ATMP service providers. Huge investments by commercial and non-commercial sponsors in testing cell-based product candidates in clinical studies will also accelerate the service provider’s market.